ADMA Biologics, Inc.
ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG proā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.46
Price-2.42%
-$0.21
1Y
Price
Market Cap
$1.961b
Small
Price/Earnings 3y Avg5y Avg
12.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+53.3%
EBITDA Margin+39.6%
Net Profit Margin+48.7%
Free Cash Flow Margin+53.3%
EBITDA Margin+39.6%
Net Profit Margin+48.7%
Free Cash Flow MarginRevenue
$509.864m
-0.1%
1y CAGR+28.2%
3y CAGR+38.1%
5y CAGREarnings
$165.354m
+12.5%
1y CAGR+262.3%
3y CAGR+211.0%
5y CAGREPS
$0.68
+13.3%
1y CAGR+236.8%
3y CAGR+195.1%
5y CAGRBook Value
$390.325m
$665.184m
Assets$274.859m
Liabilities$204.406m
DebtDebt to Assets
30.7%
0.9x
Debt to EBITDAFree Cash Flow
$107.903m
+287.9%
1y CAGR+998.7%
3y CAGR+775.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company